Intangible Assets

12 Months Ended

Dec. 31, 2015

Intangible Assets

Intangible Assets

6. Intangible Assets

        Intangible assets consist solely of core developed technology acquired as part of a 2007 asset purchase agreement with Parivid LLC. See Part I, Item 1 "Business—Collaborations, Licenses and Asset Purchases—Parivid" in this Annual Report on Form 10-K for relevant disclosures. The developed technology intangible assets are being amortized over the estimated useful life of the Enoxaparin Sodium Injection and GLATOPA developed technology of approximately 10 years. As of December 31, 2015 and December 31, 2014, intangible assets, net of accumulated amortization, are as follows (in thousands):

			2015					2014
	Weighted-Average Amortization Period (in years)		Gross Carrying Amount		Accumulated Amortization			Gross Carrying Amount		Accumulated Amortization
Total intangible assets for core and developed technology and non-compete agreement		10	$	10,427	$	(6,899	)	$	10,427	$	(5,838	)

        Amortization is computed using the straight-line method over the useful lives of the respective intangible assets as there is no other pattern of use that is reasonably estimable. Amortization expense was approximately $1.1 million in each of the years ended December 31, 2015, 2014 and 2013.

        The Company expects to incur amortization expense of appropriately $1.1 million per year for each of the next three years (2016 to 2018) and $0.3 million in the fourth year (2019).